Skip to main content
Erschienen in: Applied Health Economics and Health Policy 4/2005

01.12.2005 | Review Article

What value health?

A review of health state values used in early technology assessments for NICE

verfasst von: Dr Ken Stein, Alison Fry, Ali Round, Ruairidh Milne, John Brazier

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

The objective of this article was to review the methods used to obtain quality-of-life (utility) weights reported in assessments carried out for the National Institute for Health and Clinical Excellence (NICE).
The design of the review was a cross-sectional survey. Health technology assessment (HTA) reports published on the NICE website up to May 2003 were reviewed. Data were extracted on the following: the approach to utility estimation (direct or indirect), how health states were described for indirect estimation, valuation techniques used (standard gamble [SG], time trade-off [TTO], visual analogue scale [VAS], etc.), whether uncertainty in utility estimates was explored in cost-utility analyses, and whether utility values were identified as a priority for further research by assessment authors.
Fifty-six assessments were reviewed, of which 28 reported 45 cost-utility analyses. There was striking variation in the values used to describe different health states. Data from patients were used in 15 (33%) analyses, from the general public in 10 (22%) and from clinicians in 4 (9%). In 16 (36%) cases, the source for utility estimates was unclear. Health states were described using a range of generic and disease-specific measures, although the EQ-5D was used most frequently. In 25 analyses (56%), the valuation technique used was not reported. TTO was used in 11 (24%), SG in 3 (7%), magnitude estimation in 5 (11%) and VAS in 1 (2%). Sensitivity analyses based on utility values were reported in 25 cases (56%), more commonly in reports of analyses carried out by independent teams than technology sponsors although this may be subject to reporting bias. Further research into quality of life was recommended in 17 (61%) of the 28 assessment reports that contained at least one cost-utility analysis.
Greater transparency and consistency are required in reporting the methods used to obtain quality-of-life weights in cost-utility analyses, and better sources of data are required. Methodological variation results in important differences in values. Therefore, caution must be exercised when comparing the results of different cost-utility analyses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2003 National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2003
2.
Zurück zum Zitat Warren E, Weatherley-Jones E, Chilcott J, et al. The clinical and cost-effectiveness of long-acting insulin analogue, insulin glargine. Sheffield: School of Health and Related Research, 2002 Warren E, Weatherley-Jones E, Chilcott J, et al. The clinical and cost-effectiveness of long-acting insulin analogue, insulin glargine. Sheffield: School of Health and Related Research, 2002
3.
Zurück zum Zitat Kaltenthaler E, Shackley P, Stevens K, et al. Computerised cognitive behaviour therapy for depression and anxiety. Sheffield: ScHARR Rapid Reviews Group, School of Health and Related Research, University of Sheffield, 2002 Kaltenthaler E, Shackley P, Stevens K, et al. Computerised cognitive behaviour therapy for depression and anxiety. Sheffield: ScHARR Rapid Reviews Group, School of Health and Related Research, University of Sheffield, 2002
4.
Zurück zum Zitat Vale L, Wyness L, McCormack K, et al. Systematic review of the effectiveness and cost effectiveness of metal on metal hip resurfacing for treatment of hip disease. Aberdeen: Health Services Research Unit, University of Aberdeen, 2001 Vale L, Wyness L, McCormack K, et al. Systematic review of the effectiveness and cost effectiveness of metal on metal hip resurfacing for treatment of hip disease. Aberdeen: Health Services Research Unit, University of Aberdeen, 2001
5.
Zurück zum Zitat Jobanputra P, Barton P, Bryan S, et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Sep 3 Jobanputra P, Barton P, Bryan S, et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Sep 3
6.
Zurück zum Zitat Stewart A, Sandercock J, Bryan S, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease. Birmingham: West Midlands Development and Evaluation Service, 2000 Aug 1 Stewart A, Sandercock J, Bryan S, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease. Birmingham: West Midlands Development and Evaluation Service, 2000 Aug 1
7.
Zurück zum Zitat Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Leicester: University of Leicester/ScHARR, University of Sheffield, 2002 Apr 29 Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Leicester: University of Leicester/ScHARR, University of Sheffield, 2002 Apr 29
8.
Zurück zum Zitat Clark W, Burls A, Song F, et al. Infliximab for the treatment of Crohn’s disease. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Jul 10 Clark W, Burls A, Song F, et al. Infliximab for the treatment of Crohn’s disease. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Jul 10
9.
Zurück zum Zitat Thomas S, Prince A, Humphries C, et al. Assessment of interferon-beta and glatiramer for the treatment of multiple sclerosis. Newcastle upon Tyne: Regional Drug and Therapeutics Centre, 2000 Thomas S, Prince A, Humphries C, et al. Assessment of interferon-beta and glatiramer for the treatment of multiple sclerosis. Newcastle upon Tyne: Regional Drug and Therapeutics Centre, 2000
10.
Zurück zum Zitat Bagnall A-M, Jones L, Ginnelly L, et al. A rapid and systematic review of atypical antipsychotics in schizophrenia. York: NHS Centre for Reviews and Dissemination, 2001 Sep 21 Bagnall A-M, Jones L, Ginnelly L, et al. A rapid and systematic review of atypical antipsychotics in schizophrenia. York: NHS Centre for Reviews and Dissemination, 2001 Sep 21
11.
Zurück zum Zitat Wake B, Bryan S, Barton P, et al. Rituximab as third line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin’s lymphoma. Birmingham: Department of Public Health and Epidemiology, University of Birmingham, 2001 Jan 1 Wake B, Bryan S, Barton P, et al. Rituximab as third line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin’s lymphoma. Birmingham: Department of Public Health and Epidemiology, University of Birmingham, 2001 Jan 1
12.
Zurück zum Zitat Lloyd Jones M, Hummel S, Bansback N. A review of the evidence for the clinical and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Sheffield: The University of Sheffield School of Health and Related Research, 2001 Jan 15 Lloyd Jones M, Hummel S, Bansback N. A review of the evidence for the clinical and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Sheffield: The University of Sheffield School of Health and Related Research, 2001 Jan 15
13.
Zurück zum Zitat Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C. Southampton: Wessex Institute for Health Research & Development, 2000 Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C. Southampton: Wessex Institute for Health Research & Development, 2000
14.
Zurück zum Zitat Cody J, Wyness L, Wallace S, et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape (TVT) for treatment of urinary stress incontinence. Aberdeen: Health Services Research Unit, 2002 Aug 12 Cody J, Wyness L, Wallace S, et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape (TVT) for treatment of urinary stress incontinence. Aberdeen: Health Services Research Unit, 2002 Aug 12
15.
Zurück zum Zitat Kind P, Hardman G, Macran S. UK population norms for EQ-5D [CHE discussion paper 172]. York: University of York, 1999 Kind P, Hardman G, Macran S. UK population norms for EQ-5D [CHE discussion paper 172]. York: University of York, 1999
16.
Zurück zum Zitat Cummins C, Connock M, Fry-Smith A, et al. A rapid review of new drug treatments for juvenile idiopathic arthritis: etanercept. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Jun 8 Cummins C, Connock M, Fry-Smith A, et al. A rapid review of new drug treatments for juvenile idiopathic arthritis: etanercept. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2001 Jun 8
17.
Zurück zum Zitat Dinnes J, Cave C, Hunag S, et al. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma. Southampton: Wessex Institute for Health Research and Development, University of Southampton, 2000 Nov 27 Dinnes J, Cave C, Hunag S, et al. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma. Southampton: Wessex Institute for Health Research and Development, University of Southampton, 2000 Nov 27
18.
Zurück zum Zitat Parkes J, Bryant J, Milne R. Arrhythmias: implantable cardioverter defibrillators. Southampton: National Coordinating Centre for Health Technology Assessments (NCCHTA), University of Southampton, 2000 Nov 9 Parkes J, Bryant J, Milne R. Arrhythmias: implantable cardioverter defibrillators. Southampton: National Coordinating Centre for Health Technology Assessments (NCCHTA), University of Southampton, 2000 Nov 9
19.
Zurück zum Zitat Rosser R, Cottee M, Rabin R, et al. Index of health related quality of life. In: Hopkins A, editor. Measures of the quality of life and the uses to which such measures may be put. London: Royal College of Physicians, 1992 Rosser R, Cottee M, Rabin R, et al. Index of health related quality of life. In: Hopkins A, editor. Measures of the quality of life and the uses to which such measures may be put. London: Royal College of Physicians, 1992
20.
Zurück zum Zitat O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. York: NHS Centre for Reviews and Dissemination, University of York, 2000 Dec 7 O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. York: NHS Centre for Reviews and Dissemination, University of York, 2000 Dec 7
21.
Zurück zum Zitat Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1115–28PubMedCrossRef Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1115–28PubMedCrossRef
22.
Zurück zum Zitat Deverill M, Brazier J, Green C, et al. The use of QALY and non-QALY measures of health-related quality of life. Pharmacoeconomics 1998; 13: 411–20PubMedCrossRef Deverill M, Brazier J, Green C, et al. The use of QALY and non-QALY measures of health-related quality of life. Pharmacoeconomics 1998; 13: 411–20PubMedCrossRef
23.
Zurück zum Zitat Hawthorne G. The effect of different methods of collecting data: mail, telephone and filter data collection issues in utility measurement. Quality 2000; 12: 1081–8 Hawthorne G. The effect of different methods of collecting data: mail, telephone and filter data collection issues in utility measurement. Quality 2000; 12: 1081–8
25.
Zurück zum Zitat Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3(9): i–iv, 1-164PubMed Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3(9): i–iv, 1-164PubMed
26.
Zurück zum Zitat Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2000 Jun 30 Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2000 Jun 30
27.
Zurück zum Zitat Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996; 5: 141–54PubMedCrossRef Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996; 5: 141–54PubMedCrossRef
28.
Zurück zum Zitat Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12: 599–607PubMedCrossRef Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12: 599–607PubMedCrossRef
29.
Zurück zum Zitat Boland A, Bagust A, Hill R, et al. Early thrombolysis for the treatment of acute myocardial infarction. Liverpool: Liverpool Reviews and Implementation Group, 2002 Apr 11 Boland A, Bagust A, Hill R, et al. Early thrombolysis for the treatment of acute myocardial infarction. Liverpool: Liverpool Reviews and Implementation Group, 2002 Apr 11
30.
Zurück zum Zitat The National Institute for Clinical Excellence (NICE) Appraisal Team. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COX-II inhibitors) for rheumatoid arthritis and osteoarthritis. London: NICE, 2000 Nov 1 The National Institute for Clinical Excellence (NICE) Appraisal Team. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COX-II inhibitors) for rheumatoid arthritis and osteoarthritis. London: NICE, 2000 Nov 1
31.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
32.
Zurück zum Zitat Dolan P. Valuing health-related quality of life: issues and controversies. Pharmacoeconomics 1998; 15: 119–27CrossRef Dolan P. Valuing health-related quality of life: issues and controversies. Pharmacoeconomics 1998; 15: 119–27CrossRef
33.
Zurück zum Zitat Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978; 7: 347–58PubMedCrossRef Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978; 7: 347–58PubMedCrossRef
34.
Zurück zum Zitat Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 1997; 17: 402–8PubMedCrossRef Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 1997; 17: 402–8PubMedCrossRef
35.
Zurück zum Zitat Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997 Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
36.
Zurück zum Zitat Stalmeier PFM, Goldstein MK, Holmes AM, et al. What should be reported in a methods section on utility assessment? Med Decis Making 2001; 21: 200–7PubMed Stalmeier PFM, Goldstein MK, Holmes AM, et al. What should be reported in a methods section on utility assessment? Med Decis Making 2001; 21: 200–7PubMed
Metadaten
Titel
What value health?
A review of health state values used in early technology assessments for NICE
verfasst von
Dr Ken Stein
Alison Fry
Ali Round
Ruairidh Milne
John Brazier
Publikationsdatum
01.12.2005
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 4/2005
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/00148365-200504040-00004

Weitere Artikel der Ausgabe 4/2005

Applied Health Economics and Health Policy 4/2005 Zur Ausgabe

Acknowledgments

Acknowledgement